Assay ID | Title | Year | Journal | Article |
AID390003 | Binding affinity to human ARG at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390051 | Binding affinity to human EGFR at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720183 | Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720177 | Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390034 | Binding affinity to human TIE2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720068 | Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389591 | Binding affinity to human P38A at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720385 | Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720028 | Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389595 | Binding affinity to human CLK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720450 | Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720388 | Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720449 | Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389590 | Binding affinity to human JNK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720091 | Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720171 | Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389551 | Binding affinity to human CAMK2A at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390037 | Binding affinity to human ROS at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720457 | Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390002 | Binding affinity to human ABL at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720271 | Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720057 | Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720411 | Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720137 | Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720218 | Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720443 | Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720400 | Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720042 | Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720429 | Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390020 | Binding affinity to human FES at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720168 | Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720438 | Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID127245 | Inhibitory activity against Mitogen-activated protein kinase p38 | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
| Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. |
AID720357 | Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389588 | Binding affinity to human JNK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720460 | Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720150 | Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720281 | Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720198 | Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720143 | Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390016 | Binding affinity to human FRK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720478 | Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720060 | Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720096 | Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389533 | Binding affinity to human MSK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720052 | Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720274 | Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720176 | Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390089 | Binding affinity to human ADCK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389554 | Binding affinity to human CAMK2G at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389573 | Binding affinity to human AURA at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720173 | Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720213 | Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389560 | Binding affinity to human AMPKA2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720474 | Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720286 | Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720356 | Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390071 | Binding affinity to human JAK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720204 | Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389583 | Binding affinity to human CDK5 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720216 | Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389562 | Binding affinity to human MARK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390048 | Binding affinity to human MET at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389538 | Binding affinity to human PRKX at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720079 | Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389582 | Binding affinity to human CDK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720477 | Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720298 | Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390032 | Binding affinity to human PDGFRB at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389601 | Binding affinity to human CK2A2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720470 | Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389556 | Binding affinity to human PHKG2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720136 | Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720290 | Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720043 | Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720149 | Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720189 | Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389623 | Binding affinity to human FUSED at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389598 | Binding affinity to human CLK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720305 | Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389606 | Binding affinity to human HPK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720089 | Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720321 | Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720413 | Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720109 | Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389542 | Binding affinity to human MRCKA at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720344 | Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390056 | Binding affinity to human EPHA3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720141 | Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720031 | Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720056 | Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720394 | Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720328 | Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720023 | Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389099 | Binding affinity to human AKT2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID210785 | Dissociation constant for TGF-beta receptor type I | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). |
AID390077 | Binding affinity to human MLK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720214 | Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720329 | Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720104 | Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720472 | Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720045 | Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389587 | Binding affinity to human NLK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720407 | Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720192 | Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720245 | Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720473 | Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720217 | Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720352 | Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720379 | Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720122 | Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720037 | Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389612 | Binding affinity to human YSK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389575 | Binding affinity to human PLK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389100 | Binding affinity to human AKT3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720094 | Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389553 | Binding affinity to human CAMK2B at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720210 | Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720027 | Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720087 | Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390004 | Binding affinity to human BTK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389559 | Binding affinity to human AMPKA1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720130 | Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720062 | Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390041 | Binding affinity to human TRKB at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720479 | Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720390 | Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720256 | Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720021 | Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720125 | Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390014 | Binding affinity to human FYN at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720361 | Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720226 | Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720340 | Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720322 | Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390079 | Binding affinity to human RAF1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390000 | Binding affinity to human ACTR2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720069 | Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720452 | Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720086 | Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720372 | Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID330483 | Permeability from apical to basolateral side of human Caco-2 cell membrane | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID720448 | Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720202 | Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720097 | Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720169 | Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720044 | Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720427 | Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720209 | Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390087 | Binding affinity to human TTK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390042 | Binding affinity to human TRKC at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720159 | Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389561 | Binding affinity to human BRSK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389619 | Binding affinity to human PAK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720161 | Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389999 | Binding affinity to human BMPR1A at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720389 | Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390062 | Binding affinity to human EPHB2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720227 | Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720428 | Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389629 | Binding affinity to human TLK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720482 | Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720334 | Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720127 | Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389611 | Binding affinity to human MST3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720103 | Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389625 | Binding affinity to human NEK9 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720132 | Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389626 | Binding affinity to human NEK6 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390086 | Binding affinity to human MPSK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720175 | Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720299 | Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720446 | Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390028 | Binding affinity to human FLT4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720205 | Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720463 | Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389616 | Binding affinity to human PAK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720100 | Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720461 | Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720228 | Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720224 | Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID447434 | Inhibition of TGFR1 | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
| Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. |
AID389563 | Binding affinity to human MARK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720336 | Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720231 | Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720162 | Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720246 | Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720163 | Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720020 | Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720442 | Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389613 | Binding affinity to human MST4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720241 | Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720380 | Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720320 | Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720055 | Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID330429 | Inhibition of TGFbeta type receptor 1 ALK5 (T204D) expressed in Sf9 cells | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID720077 | Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389622 | Binding affinity to human ULK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720323 | Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720467 | Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720484 | Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720304 | Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720354 | Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720480 | Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720152 | Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720251 | Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720365 | Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720041 | Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720430 | Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720048 | Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720253 | Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720462 | Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720368 | Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720172 | Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720465 | Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720313 | Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720221 | Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720059 | Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720434 | Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390033 | Binding affinity to human FLT3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390076 | Binding affinity to human HH498 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720403 | Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720259 | Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720117 | Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390031 | Binding affinity to human PDGFRA at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720475 | Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390054 | Binding affinity to human SYK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720261 | Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389532 | Binding affinity to human PKN2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720337 | Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389605 | Binding affinity to human KHS2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720421 | Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720107 | Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720406 | Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720036 | Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720333 | Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720371 | Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720095 | Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390007 | Binding affinity to human ITK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720083 | Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720151 | Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720383 | Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720030 | Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390072 | Binding affinity to human TYK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389604 | Binding affinity to human KHS1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720433 | Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720120 | Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390050 | Binding affinity to human TNK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720129 | Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720032 | Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390015 | Binding affinity to human FGR at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390005 | Binding affinity to human BMX at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720346 | Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389084 | Binding affinity to human ARG | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389632 | Binding affinity to human GAK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390066 | Binding affinity to human EPHA2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389614 | Binding affinity to human SLK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389593 | Binding affinity to human P38G at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720067 | Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720359 | Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720054 | Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720453 | Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720373 | Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390082 | Binding affinity to human CK1d at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720378 | Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720289 | Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720066 | Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720381 | Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720058 | Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720242 | Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389596 | Binding affinity to human CLK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390024 | Binding affinity to human FGFR4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389565 | Binding affinity to human QIK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID127083 | In vitro inhibitory activity against Mitogen-activated protein kinase p38 | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID720273 | Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389998 | Binding affinity to human TGFBR1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720206 | Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390065 | Binding affinity to human EPHA8 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720410 | Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389531 | Binding affinity to human PKCH at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720185 | Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389539 | Binding affinity to human PKACB at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID210784 | Inhibition of Transforming growth factor beta-1 receptor (TbetaRI) autophosphorylation | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). |
AID720203 | Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720341 | Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720466 | Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720348 | Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389608 | Binding affinity to human TNIK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390067 | Binding affinity to human EPHA1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720353 | Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720287 | Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390022 | Binding affinity to human FGFR3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720349 | Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720317 | Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720435 | Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720363 | Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720415 | Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389546 | Binding affinity to human YANK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720230 | Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720266 | Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720347 | Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720115 | Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390075 | Binding affinity to human TESK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720297 | Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389569 | Binding affinity to human CAMKK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389574 | Binding affinity to human PLK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720469 | Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720483 | Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720244 | Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720128 | Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720101 | Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390029 | Binding affinity to human FMS at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390083 | Binding affinity to human CK1e at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720110 | Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390011 | Binding affinity to human BLK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389607 | Binding affinity to human HGK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720070 | Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720165 | Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720249 | Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720431 | Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390046 | Binding affinity to human MER at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720232 | Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389600 | Binding affinity to human CK2A1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720065 | Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720358 | Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390049 | Binding affinity to human ACK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720063 | Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720082 | Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720396 | Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390081 | Binding affinity to human CK1a2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720145 | Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720195 | Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390084 | Binding affinity to human CK1gamma1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720240 | Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID1192461 | Antimigratory activity against human MDA-MB-231 cells assessed as reduction in formation of tubule-like structures at 275 nM after 16 hrs by matrigel assay relative to untreated control | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
| 4-Dechloro-14-deoxy-oxacyclododecindione and 14-deoxy-oxacylododecindione, two inhibitors of inducible connective tissue growth factor expression from the imperfect fungus Exserohilum rostratum. |
AID389548 | Binding affinity to human CAMK1A at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720018 | Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720399 | Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720170 | Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389597 | Binding affinity to human CLK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389571 | Binding affinity to human AURC at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389621 | Binding affinity to human PAK6 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720078 | Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389618 | Binding affinity to human PAK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720402 | Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720418 | Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720258 | Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390078 | Binding affinity to human BRAF at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390019 | Binding affinity to human FER at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720455 | Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720178 | Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720366 | Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720260 | Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID330474 | Metabolic stability in human liver microsomes | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID389624 | Binding affinity to human NEK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID261606 | Inhibition of TGFbeta R1 induced transcriptional activation of p3TP-Lux in mink Mv1Lu lung cells | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. |
AID720267 | Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720318 | Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720331 | Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390088 | Binding affinity to human ADCK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720312 | Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390044 | Binding affinity to human MUSK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389550 | Binding affinity to human CAMK1G at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720398 | Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720325 | Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720138 | Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID261607 | Inhibitory activity against TGF-beta-stimulated proliferation in NIH3T3 cells | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. |
AID720294 | Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720306 | Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720142 | Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID132673 | In vitro inhibition of transforming growth factor- beta dependent luciferase growth in mouse fibroblasts (NIH 3T3) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID389628 | Binding affinity to human TLK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390006 | Binding affinity to human TXK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390060 | Binding affinity to human EPHA7 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID330430 | Antiproliferative activity against mink Mv1Lu-p3TP-Lux cells by luciferase reporter assay | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID720283 | Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720112 | Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389633 | Binding affinity to human GCN2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720111 | Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720024 | Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720073 | Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390035 | Binding affinity to human ALK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720155 | Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720386 | Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720075 | Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389609 | Binding affinity to human MST1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390026 | Binding affinity to human KDR at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720167 | Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389634 | Binding affinity to human MYT1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389555 | Binding affinity to human PHKG1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720124 | Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390009 | Binding affinity to human LYN at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720215 | Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390073 | Binding affinity to human LIMK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390001 | Binding affinity to human ACTR2B at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389552 | Binding affinity to human CAMK2D at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390038 | Binding affinity to human INSR at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720351 | Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720255 | Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389637 | Binding affinity to human ALK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390052 | Binding affinity to human ERBB2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389584 | Binding affinity to human PCTAIRE1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389544 | Binding affinity to human NDR2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720051 | Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720219 | Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720076 | Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720268 | Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720033 | Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720374 | Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720134 | Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720236 | Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720186 | Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390059 | Binding affinity to human EPHA6 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720053 | Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720108 | Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720458 | Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720364 | Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389610 | Binding affinity to human MST2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720432 | Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720182 | Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390027 | Binding affinity to human FLT1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720459 | Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720342 | Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390018 | Binding affinity to human CSK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389636 | Binding affinity to human ALK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720237 | Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390057 | Binding affinity to human EPHA5 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720234 | Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390061 | Binding affinity to human EPHB1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720464 | Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720345 | Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720098 | Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720199 | Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720420 | Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID261603 | Inhibition of recombinant human TGFbeta R1 expressed in Sf9 cells | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. |
AID720099 | Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720046 | Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720384 | Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720194 | Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720454 | Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720417 | Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720026 | Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389564 | Binding affinity to human MARK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720367 | Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389602 | Binding affinity to human MAP3K5 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720243 | Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720270 | Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720412 | Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720239 | Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390040 | Binding affinity to human IRR at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720201 | Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720174 | Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389630 | Binding affinity to human AAK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720301 | Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720395 | Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720135 | Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720039 | Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390013 | Binding affinity to human YES at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720247 | Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389557 | Binding affinity to human MNK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720093 | Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720362 | Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390074 | Binding affinity to human LIMK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720326 | Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720156 | Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720392 | Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720387 | Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720035 | Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720275 | Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720330 | Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720047 | Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720391 | Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720269 | Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720291 | Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389585 | Binding affinity to human ERK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390063 | Binding affinity to human EPHB3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720441 | Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720324 | Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389579 | Binding affinity to human DRAK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720309 | Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720264 | Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720140 | Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720424 | Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720288 | Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720116 | Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390010 | Binding affinity to human LCK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389549 | Binding affinity to human CAMK1D at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720303 | Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720310 | Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720238 | Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720355 | Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID126446 | In vitro inhibition of transforming growth factor- beta dependent luciferase production in mink lung cells (p3TP Lux) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID390030 | Binding affinity to human KIT at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720017 | Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720222 | Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720444 | Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720393 | Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720126 | Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720085 | Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389631 | Binding affinity to human BIKE at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720335 | Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390008 | Binding affinity to human HCK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390043 | Binding affinity to human TRKA at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720034 | Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390055 | Binding affinity to human ZAP70 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720164 | Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389580 | Binding affinity to human DRAK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720250 | Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720131 | Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720235 | Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720119 | Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720081 | Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389572 | Binding affinity to human AURB at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720282 | Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720049 | Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720302 | Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389570 | Binding affinity to human LKB1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID390053 | Binding affinity to human ERBB4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720158 | Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720278 | Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720279 | Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389627 | Binding affinity to human NEK7 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389547 | Binding affinity to human YANK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720436 | Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720106 | Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389594 | Binding affinity to human GSK3A at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720440 | Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720121 | Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390070 | Binding affinity to human JAK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720307 | Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389577 | Binding affinity to human DAPK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID210786 | Inhibition of human Transforming growth factor (TGF) beta-1 receptor (T204D mutation) autophosphorylation in Sf9 cells | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
| Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID720476 | Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720208 | Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720148 | Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390012 | Binding affinity to human SRC at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720212 | Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720414 | Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390039 | Binding affinity to human IGF1R at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720481 | Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389620 | Binding affinity to human PAK5 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720113 | Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720090 | Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720292 | Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389615 | Binding affinity to human LOK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720040 | Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720382 | Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720277 | Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720200 | Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390025 | Binding affinity to human RET at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389576 | Binding affinity to human PLK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720118 | Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720315 | Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720071 | Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720471 | Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389541 | Binding affinity to human PKG2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389558 | Binding affinity to human STK33 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389280 | Binding affinity to human PKCA at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389098 | Binding affinity to human AKT1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID330475 | Metabolic stability in rat microsomes | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID261605 | Inhibition of MLK7 | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. |
AID720184 | Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390100 | Inhibition of TGFBR1 | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720088 | Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720262 | Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720207 | Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720153 | Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720332 | Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389568 | Binding affinity to human CAMKK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720377 | Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389534 | Binding affinity to human MSK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389537 | Binding affinity to human RSK4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389535 | Binding affinity to human RSK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720419 | Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720375 | Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390069 | Binding affinity to human PYK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720025 | Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720160 | Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720225 | Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720451 | Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720133 | Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720181 | Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720327 | Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720285 | Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID86693 | Inhibition of TGF-beta-induced expression of PAI-luciferase reporter in HepG2 cells | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
| Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). |
AID720404 | Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720092 | Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720029 | Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390080 | Binding affinity to human RIPK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720233 | Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390068 | Binding affinity to human FAK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720401 | Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390021 | Binding affinity to human FGFR2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720408 | Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720180 | Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390045 | Binding affinity to human AXL at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720422 | Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720405 | Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720019 | Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720223 | Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389566 | Binding affinity to human PIM1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720293 | Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720350 | Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390064 | Binding affinity to human EPHB4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720220 | Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID330431 | Antiproliferative activity against mouse NIH3T3 cells by [3H]thymidine assay | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
AID720229 | Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390058 | Binding affinity to human EPHA4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720314 | Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389543 | Binding affinity to human DMPK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389540 | Binding affinity to human PKG1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720263 | Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720311 | Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720038 | Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720426 | Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720319 | Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390017 | Binding affinity to human BRK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720284 | Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720265 | Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389578 | Binding affinity to human DAPK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720080 | Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720188 | Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720308 | Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720300 | Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720338 | Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389581 | Binding affinity to human SKMLCK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720339 | Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720074 | Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720050 | Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720187 | Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720439 | Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720416 | Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720296 | Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720146 | Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720022 | Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720197 | Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720064 | Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID261604 | Inhibition of recombinant human TGFbeta R2 expressed in Sf9 cells | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
| Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. |
AID720360 | Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390023 | Binding affinity to human FGFR1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720211 | Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720447 | Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720102 | Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720166 | Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389536 | Binding affinity to human RSK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720370 | Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720376 | Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720295 | Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720423 | Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720456 | Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390047 | Binding affinity to human TYRO3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720193 | Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720343 | Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720179 | Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720468 | Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720191 | Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720425 | Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720252 | Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389545 | Binding affinity to human PDK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720257 | Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720072 | Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720144 | Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720272 | Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720139 | Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720105 | Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389603 | Binding affinity to human MAP3K4 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720061 | Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720123 | Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720409 | Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389589 | Binding affinity to human JNK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389586 | Binding affinity to human ERK2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720437 | Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720147 | Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720114 | Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720084 | Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720190 | Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390085 | Binding affinity to human CK1g2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720445 | Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389635 | Binding affinity to human ALK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID709640 | Inhibition of TGFBR1 | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling. |
AID720276 | Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720369 | Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720248 | Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720154 | Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389599 | Binding affinity to human SRPK1 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720397 | Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720196 | Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389592 | Binding affinity to human P38B at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720280 | Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID389567 | Binding affinity to human PIM2 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID720316 | Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720157 | Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID720254 | Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA | 2013 | The Biochemical journal, Apr-15, Volume: 451, Issue:2
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
AID390036 | Binding affinity to human LTK at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID389617 | Binding affinity to human PAK3 at 10 uM relative to control | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
| Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID1811 | Experimentally measured binding affinity data derived from PDB | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
| Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. |
AID1345533 | Human transforming growth factor beta receptor 1 (Type I receptor serine/threonine kinases) | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
| Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1798091 | Enzyme Assay and Luciferase Reporter Assay from Article 10.1021/jm701199p: \\Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-beta Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growt | 2008 | Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
| Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |